EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preclinical assessment of drug–drug interaction of fb‐PMT , a novel anti‐cancer thyrointegrin αvβ3 antagonist

Kazutoshi Fujioka, Mostafa I Fekry, Jeanne M Rumsey, Toni Steiner, David Thompson, Shaker A Mousa iD

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Kazutoshi Fujioka und 5 weiteren Autor:innen. Beteiligte Einrichtung: NanoPharmaceuticals LLC, Rensselaer, New York, USA. Hauptthemen laut MEDLINE: Organic Anion Transporters, Sodium-Independent, Organic Anion Transporters. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of the current study was to identify potential drug–drug interactions (DDIs) with the drug candidate fb‐PMT, a novel anticancer thyrointegrin αvß3 antagonist. This was accomplished by using several in vitro assays to study interactions of fb‐PMT with both cytochrome P450 (CYP) enzymes and drug transporters, two common mechanisms leading to adverse drug effects. In vitro experiments showed that fb‐PMT exhibited weak reversible inhibition of CYP2C19 and CYP3A4. In addition, fb‐PMT did not show time‐dependent inhibition with any of the seven CYP isoforms tested, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4. Human liver microsomal incubations demonstrated that fb‐PMT is stable. Potential transporter‐mediated DDIs with fb‐PMT were assessed with two ATP binding cassette (ABC) family transporters (P‐glycoprotein and breast cancer resistance protein) using Caco2 cells and seven solute carrier family (SLC) transporters (organic cation transporter OCT2, organic anion transporters OAT1 and OAT3, organic anion transporter peptides OATP1B1 and OATP1B3, and the multidrug and toxic extrusion proteins MATE1 and MATE2‐K using transfected HEK293 cells). Fb‐PMT was not a substrate for any of the nine transporters tested in this study, nor did it inhibit the activity of seven of the transporters tested. However, fb‐PMT inhibited the uptake of rosuvastatin by both OATP1B1 and OATP1B3 with half‐maximal inhibitory concentrations greater than 3 and less than 10 μM. In summary, data suggest that the systemic administration of fb‐PMT is unlikely to lead to DDIs through CYP enzymes or ABC and SLC transporters in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organic Anion Transporters, Sodium-IndependentOrganic Anion TransportersHumansATP Binding Cassette Transporter, Subfamily G, Member 2Caco-2 CellsHEK293 CellsNeoplasm ProteinsMembrane Transport ProteinsDrug InteractionsATP-Binding Cassette Transporters

Substanzen

Organic Anion Transporters, Sodium-IndependentATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsMembrane Transport ProteinsATP-Binding Cassette TransportersOrganic Anion Transporters

Autor:innen und Institutionen

  • NanoPharmaceuticals LLC, Rensselaer, New York, USA.
  • Inotiv, Maryland Heights, Missouri, USA.
  • Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

ORCID-Profile: Shaker A Mousa

Zitieren

APA

Fujioka, K., Fekry, M. I., Rumsey, J. M., Steiner, T., Thompson, D., & Mousa, S. A. (2023). Preclinical assessment of drug–drug interaction of fb‐PMT , a novel anti‐cancer thyrointegrin αvβ3 antagonist. Clinical and Translational Science. https://doi.org/10.1111/cts.13504

Vancouver

Fujioka K, Fekry MI, Rumsey JM, Steiner T, Thompson D, Mousa SA. Preclinical assessment of drug–drug interaction of fb‐PMT , a novel anti‐cancer thyrointegrin αvβ3 antagonist. Clinical and Translational Science. 2023. doi:10.1111/cts.13504

BibTeX
@article{Fujioka2023,
  author = {Fujioka, Kazutoshi and Fekry, Mostafa I and Rumsey, Jeanne M and Steiner, Toni and Thompson, David and Mousa, Shaker A},
  title = {Preclinical assessment of drug–drug interaction of fb‐PMT , a novel anti‐cancer thyrointegrin αvβ3 antagonist},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13504}
}
Kostenlos starten →